SARS-CoV-2 and the safety margins of cell-based biological medicinal products

With the pandemic emergence of SARS-CoV-2, the exposure of cell substrates used for manufacturing of medicines has become a possibility. Cell lines used in biomanufacturing were thus evaluated for their SARS-CoV-2 susceptibility, and the detection of SARS-CoV-2 in culture supernatants by routine adv...

Descripción completa

Detalles Bibliográficos
Autores principales: Modrof, Jens, Kerschbaum, Astrid, Farcet, Maria R., Niemeyer, Daniela, Corman, Victor M., Kreil, Thomas R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Authors. Published by Elsevier Ltd on behalf of International Alliance for Biological Standardization. 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7456270/
https://www.ncbi.nlm.nih.gov/pubmed/32891497
http://dx.doi.org/10.1016/j.biologicals.2020.08.010
_version_ 1783575766437462016
author Modrof, Jens
Kerschbaum, Astrid
Farcet, Maria R.
Niemeyer, Daniela
Corman, Victor M.
Kreil, Thomas R.
author_facet Modrof, Jens
Kerschbaum, Astrid
Farcet, Maria R.
Niemeyer, Daniela
Corman, Victor M.
Kreil, Thomas R.
author_sort Modrof, Jens
collection PubMed
description With the pandemic emergence of SARS-CoV-2, the exposure of cell substrates used for manufacturing of medicines has become a possibility. Cell lines used in biomanufacturing were thus evaluated for their SARS-CoV-2 susceptibility, and the detection of SARS-CoV-2 in culture supernatants by routine adventitious virus testing of fermenter harvest tested.
format Online
Article
Text
id pubmed-7456270
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher The Authors. Published by Elsevier Ltd on behalf of International Alliance for Biological Standardization.
record_format MEDLINE/PubMed
spelling pubmed-74562702020-08-31 SARS-CoV-2 and the safety margins of cell-based biological medicinal products Modrof, Jens Kerschbaum, Astrid Farcet, Maria R. Niemeyer, Daniela Corman, Victor M. Kreil, Thomas R. Biologicals Article With the pandemic emergence of SARS-CoV-2, the exposure of cell substrates used for manufacturing of medicines has become a possibility. Cell lines used in biomanufacturing were thus evaluated for their SARS-CoV-2 susceptibility, and the detection of SARS-CoV-2 in culture supernatants by routine adventitious virus testing of fermenter harvest tested. The Authors. Published by Elsevier Ltd on behalf of International Alliance for Biological Standardization. 2020-11 2020-08-29 /pmc/articles/PMC7456270/ /pubmed/32891497 http://dx.doi.org/10.1016/j.biologicals.2020.08.010 Text en © 2020 The Authors Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
spellingShingle Article
Modrof, Jens
Kerschbaum, Astrid
Farcet, Maria R.
Niemeyer, Daniela
Corman, Victor M.
Kreil, Thomas R.
SARS-CoV-2 and the safety margins of cell-based biological medicinal products
title SARS-CoV-2 and the safety margins of cell-based biological medicinal products
title_full SARS-CoV-2 and the safety margins of cell-based biological medicinal products
title_fullStr SARS-CoV-2 and the safety margins of cell-based biological medicinal products
title_full_unstemmed SARS-CoV-2 and the safety margins of cell-based biological medicinal products
title_short SARS-CoV-2 and the safety margins of cell-based biological medicinal products
title_sort sars-cov-2 and the safety margins of cell-based biological medicinal products
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7456270/
https://www.ncbi.nlm.nih.gov/pubmed/32891497
http://dx.doi.org/10.1016/j.biologicals.2020.08.010
work_keys_str_mv AT modrofjens sarscov2andthesafetymarginsofcellbasedbiologicalmedicinalproducts
AT kerschbaumastrid sarscov2andthesafetymarginsofcellbasedbiologicalmedicinalproducts
AT farcetmariar sarscov2andthesafetymarginsofcellbasedbiologicalmedicinalproducts
AT niemeyerdaniela sarscov2andthesafetymarginsofcellbasedbiologicalmedicinalproducts
AT cormanvictorm sarscov2andthesafetymarginsofcellbasedbiologicalmedicinalproducts
AT kreilthomasr sarscov2andthesafetymarginsofcellbasedbiologicalmedicinalproducts

Ejemplares similares